Starpharma Holdings Limited (SPL:ASX)

$1.14

right-arrow Created with Sketch. -0.03 (-2.58%)
MCAP $473.2M
Last trade 16.10pm 20/10/2021 20mins delayed

Latest Announcements

12/10/2021SPLStarpharma Holdings Limited
08/10/2021 Price SensitivePSSPLStarpharma Holdings Limited
01/10/2021SPLStarpharma Holdings Limited
01/10/2021SPLStarpharma Holdings Limited
01/10/2021SPLStarpharma Holdings Limited
15/09/2021SPLStarpharma Holdings Limited
13/09/2021SPLStarpharma Holdings Limited
31/08/2021SPLStarpharma Holdings Limited

Company Overview

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The Company is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. It is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The Company has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The Company develops several products internally and others via commercial partnerships.

SPL in the news

Starpharma (SPL) signs a deal with ADMENTA Italia Group for its VIRALEZE…
Starpharma (SPL) releases its full-year results for FY21, with the period highlighted…
Starpharma (SPL) has latest data on efficacy of its VIRALEZE antiviral nasal…
Starpharma (SPL) has found its antiviral VIRALEZE candidate is well tolerated and…

Search Previous Announcements